Etavopivat Improves Anemia and Hemolysis in Sickle Cell Disease
According to results of a multiple-dose studies at the 2021 ASH Annual Meeting, treatment with etavopivat, a small molecule activator of erythrocyte pyruvate kinase, improved anemia and decreased intravascular hemolysis in patients with sickle cell disease (SCD) treated for up to 12 weeks. Previous studies demonstrated that etavopivat resulted in decreased levels of 2,3-disphosphoglyceric acid (2,3-DPG) and increased levels of adenosine triphosphate (ATP) in red blood cells (RBCs) of healthy volunteers and patients with SCD. In the present analysis, researchers evaluated the effects of etavopivat in two-week multiple ascending dose ...
Advertisement
Advertisement
Advertisement
Advertisement